Clinical Trial Update: Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

View source ↗

Summary

This clinical trial update reports long-term safety data for tofacitinib (CP-690,550) in subjects with rheumatoid arthritis who participated in prior studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Status: COMPLETED | Results posted: 2013-01-01